<DOC>
	<DOCNO>NCT00524004</DOCNO>
	<brief_summary>This Phase II , randomize , double-blind , placebo-controlled study design investigate whether hyperimmune bovine milk IgG product specific CsbD CS17 , protect subject diarrhea upon challenge CS-17-ETEC strain LSN03-016011/A . The study also evaluate safety tolerability bovine milk IgG product describe immune response follow challenge . The primary study objective : 1 ) Assess safety anti-CsbD anti-CS17 bovine milk IgG among healthy adult volunteer orally administer three time day 7 day . 2 ) Determine efficacy anti-CsbD bovine milk IgG preparation ETEC diarrhea upon challenge CS17-ETEC , 3 ) Determine efficacy anti-CS17 bovine milk IgG preparation ETEC diarrhea upon challenge CS17-ETEC . A secondary objective determine efficacy anti-CsbD anti-CS17 bovine milk IgG preparation moderate severe ETEC diarrhea upon challenge CS17-ETEC .</brief_summary>
	<brief_title>Safety Efficacy Bovine Milk Immunoglobulin Against CS17 CsbD</brief_title>
	<detailed_description>The primary study objective : 1 ) Assess safety anti-CsbD anti-CS17 bovine milk IgG among healthy adult volunteer orally administer three time day 7 day . 2 ) Determine efficacy anti-CsbD bovine milk IgG preparation ETEC diarrhea upon challenge CS17-ETEC , 3 ) Determine efficacy anti-CS17 bovine milk IgG preparation ETEC diarrhea upon challenge CS17-ETEC . A secondary objective determine efficacy anti-CsbD anti-CS17 bovine milk IgG preparation moderate severe ETEC diarrhea upon challenge CS17-ETEC . STUDY DESIGN This Phase II , randomize , double-blind , placebo-controlled study design investigate whether hyperimmune bovine milk IgG product specific CsbD CS17 , protect subject diarrhea upon challenge CS-17-ETEC strain LSN03-016011/A . The study also evaluate safety tolerability bovine milk IgG product describe immune response follow challenge . Subjects ( N=39 ) randomize three group receive anti-CS17 bovine milk IgG , anti-CsbD bovine milk IgG , placebo control ( commercially available lactose-free infant formula call LactoFree® Lipil® ) study day -2 . Subjects receive three dos day test article 15 minute ( range 10 - 25 minute ) three daily meal ( breakfast , lunch dinner ) period 7 day ( i.e. , study day -2 study day 4 ) . The study divide two cohort , An initial cohort 9 subject ( 3 per treatment group ) , admit General Clinical Research Center ( GCRC ) Johns Hopkins Hospital initial test bovine milk IgG product . A second cohort 30 subject admit Bayview inpatient facility complete prophylaxis study . Logistical consideration and/or withdrawal disqualification prior admission randomization , prior receive ETEC challenge , may require third cohort admit either facility . Allowing contingency , minimum number subject challenge ETEC 33 total maximum number subject 42 . The GCRC Project Review Committee review protocol prior subject admission GCRC . A brief description two inpatient facility use study provide Section 6.1.2 . Unit dose test article powder ( detail Table 5 ) suspend 150 mL water contain 2 gram sodium bicarbonate buffer . Doses test articles/placebo prepare study staff supervision research pharmacist . The study staff involve dose preparation collect clinical data subject . On fourth day inpatient phase ( study day 0 ) , morning meal receipt test article/placebo , subject give 120mL sodium bicarbonate buffer neutralize stomach acidity . About 1 minute later ingest dose CS17-ETEC strain LSN03-016011/A ( 5 X 109 cfu ) dilute 30 ml sodium bicarbonate buffer . Subjects continue receive three dos day test articles/placebo study day 4 . Subjects meet preset criterion treat antibiotic within 24 hour determination investigator test article/placebo administration discontinue initiation treatment . Subjects receive early antibiotic treatment start antibiotic treatment study day 5 . Routine discharge schedule day 7 , subject expect meet discharge criterion : feel well ( clinical symptom resolve resolve take least one dose antibiotic 1 stool culture negative challenge strain . Subjects may discharge early day 7 case-by-case basis meet discharge criterion . The duration active study period approximately seven month , encompass 6 1/2 week screening/enrollment , 4 week inpatient/outpatient phase data sample collect , 12 week immunology assay , 2 month analysis report .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Male female 18 45 year age 2 . General good health , without significant medical illness , abnormal physical exam finding clinically significant lab abnormality , determine PI 3 . Demonstrate comprehension protocol procedure knowledge ETEC illness pass write exam ( pas grade ≥ 70 % ) 4 . Willing participate inform consent obtain 5 . Available planned followup visit 6 . Negative serum pregnancy test screening ; day admission inpatient phase female subject childbearing potential . Females childbearing potential must agree use efficacious hormonal barrier method birth control study . Abstinence acceptable . Female unable bear child must document ( e.g. , tubal ligation hysterectomy ) . 1 . Presence significant medical condition psychiatric condition , gastrointestinal disease ( peptic ulcer , active gastritis gastroesophageal reflux disease , inflammatory bowel disease ) , alcohol illicit drug abuse/dependency , lab abnormality opinion investigator precludes participation study 2 . Immunosuppressive illness IgA deficiency ( normal limit ) 3 . Positive serology result HIV HCV antibody , HBsAg 4 . Significant abnormality screen hematology , serum chemistry , urinalysis EKG ( EKG subject ≥ 40 year ) , determine PI 5 . Allergy fluoroquinolones , trimethoprimsulfamethoxazole , ampicillin/penicillin ( exclude allergic 2 3 ) 6 . Fewer 3 stool per week 3 stool per day regular basis . 7 . History diarrhea 2 week prior plan inpatient phase 8 . Regular use laxative , antacid , agent low stomach acidity ( regular = least weekly ) 9 . Use antibiotic 7 day dose proton pump inhibitor , H2 blocker , antacid within 48 hour dose ( bovine milk IgG ) . 10 . Travel country ETEC cholera infection endemic ( develop world ) within 2 year prior bovine milk IgG dose 11 . History vaccination ingestion ETEC , cholera , LT toxin . 12 . Stool culture ( collect 1 week prior admission ) positive ETEC bacterial enteric pathogen ( include Salmonella , Shigella Campylobacter ) 13 . Use investigational drug investigational vaccine within 30 day precede first dose test article/placebo , plan use active study period 14 . Clinical history lactose intolerance allergy milk milk product 15 . Use medication know affect immune function ( e.g. , corticosteroid ) within 30 day precede first dose test article/placebo , plan use active study period . ( Topical intraarticular steroid exclude subject . ) 16 . Inability tolerate overthecounter , lactosefree , infant , powder formula suspend 150 mL sodium bicarbonate buffer ( base requirement frequent dosing ) Subjects receive dose test article 3 time daily 15 minute ( range 1025 minute ) meal 7 day . The dose consist 2.4 gm antiCS17 bovine milk IgG , 2.3 gm antiCsbD bovine milk IgG 2.8 gm LactoFree® powder suspend 150 mL water contain 2 gram sodium bicarbonate buffer . Breakfast 1st daily dose test article describe Following 90minute fast , subject ingest 120 ml sodium bicarbonate buffer neutralize stomach acidity . One minute later ( 2 minute ) subject ingest CS17ETEC challenge inoculum dilute 30ml sodium bicarbonate buffer . Fifteen minute ( range : 1025 minute ) drink CS17ETEC inoculum , subject ingest second ( Day 0 ) dose bovine milk IgG test article placebo . No IgG test article administer immediately follow lunch day challenge .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Passive immunization , Bovine Milk Immunoglobulin</keyword>
</DOC>